Completed
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
NCT03526250· Phase 2· National Cancer Institute (NCI)· Source
Completed
Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors
NCT03206450· Children's Oncology Group· Source
Completed
Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer
NCT03223753· Phase 3· Children's Oncology Group· Source
Completed
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
NCT03213678· Phase 2· National Cancer Institute (NCI)· Source
Completed
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
NCT03213665· Phase 2· National Cancer Institute (NCI)· Source
Completed
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
NCT03220035· Phase 2· National Cancer Institute (NCI)· Source
Completed
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
NCT03213691· Phase 2· National Cancer Institute (NCI)· Source
Completed
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
NCT03233204· Phase 2· National Cancer Institute (NCI)· Source
Completed
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
NCT02828358· Phase 2· National Cancer Institute (NCI)· Source
Completed
Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma
NCT02470091· Phase 2· Children's Oncology Group· Source
Completed
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
NCT01979536· Phase 2· National Cancer Institute (NCI)· Source
Completed
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
NCT01798004· Phase 1· Children's Oncology Group· Source
Completed
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
NCT01553149· Phase 2· National Cancer Institute (NCI)· Source
Completed
Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors
NCT01602666· Phase 2· Children's Oncology Group· Source
Completed
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
NCT02883049· Phase 3· National Cancer Institute (NCI)· Source
Completed
Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma
NCT01236560· Phase 2/3· National Cancer Institute (NCI)· Source
Completed
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
NCT01231906· Phase 3· Children's Oncology Group· Source
Completed
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma
NCT01096368· Phase 3· Children's Oncology Group· Source
Completed
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
NCT00945009· Phase 3· Children's Oncology Group· Source
Completed
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET
NCT00392327· Phase 3· Children's Oncology Group· Source
Completed
Collecting and Storing Tissue From Young Patients With Cancer
NCT00898755· Children's Oncology Group· Source
Completed
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
NCT00408005· Phase 3· National Cancer Institute (NCI)· Source
Completed
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor
NCT00352534· Phase 3· Children's Oncology Group· Source
Completed
Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease
NCT00107198· Phase 2· Children's Oncology Group· Source
Completed
Study of Kidney Tumors in Younger Patients
NCT00898365· Children's Oncology Group· Source
Completed
Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma
NCT00085735· Phase 3· Children's Oncology Group· Source
Completed
Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors
NCT00082745· Children's Oncology Group· Source
Completed
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
NCT00026312· Phase 3· National Cancer Institute (NCI)· Source
Completed
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
NCT00904241· Children's Oncology Group· Source